Lead candidates were further evaluated against [3H]OXD-2115 in human postmortem AD and PSP tissues for comparison with first- and second-generation PET radiopharmaceuticals for imaging tau aggregation (Table 1). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.